Null mutations for carboxypeptidase 4 (Cpa4) have yet to be created from targeted embryonic stem cells (www.informatics.jax.org, 18 Feb 2014); however, CPA4 polymorphisms in humans are associated with early onset intermediate to high risk prostate cancer [72]. Here, CPA4 is linked to prostate carcinoma.